Close mobile menu×
Close mobile menu

Michio Hirano, MD

Board Certifications: 
Neuromuscular Medicine, Neurology
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-1319

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Neuromuscular Medicine
  • Neurology

Clinical Expertise

  • Neuromuscular Disease
  • Myopathy
  • Muscular Dystrophy
  • Myoneural Disorder
  • Neurometabolic Disorder
  • Myasthenia Gravis
  • Neuromuscular junction disorders

Specialties

Education & Training

  • Albert Einstein College of Medicine of Yeshiva University
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Honors & Awards

America's Best Doctors

Elected member of the American Neurological Association

Elected Fellow of the American Academy of Neurology

About Michio Hirano

Dr. Hirano received his B.A. from Harvard College and M.D. from the Albert Einstein College of Medicine. At the Columbia University Medical Center (CUMC), he did his neurology residency training and a post-doctoral fellowship in neuromuscular genetics under Drs. Salvatore DiMauro and Eric Schon.

Currently, Dr. Hirano serves as Chief of the Neuromuscular Division, Co-Director of the CUMC Muscular Dystrophy Association clinic, and Director of the H. Houston Merritt Center for Muscular Dystrophy and Related Diseases. He evaluated patients with myopathies and other neuromuscular disorders.

Academic Titles

  • Professor of Neurology

Administrative Positions

  • Chief, Division of Neuromuscular Disorders
  • Director, H. Houston Merritt Clinical Research Center
  • Medical Director, Laboratory of Molecular Genetics/Laboratory of Metabolic and Mitochondrial Disease

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
710 West 168th Street
New York, New York 10032
Phone:
(212) 305-1319
Primary

Research

Dr. Hirano's research focuses on mitochondrial diseases and genetic myopathies. He is participating in the clinical trial of idebenone for MELAS patients. Together with Co-Principal Investigators, Drs. Salvatore DiMauro and J.L.P (Seamus) Thompson, Dr. Hirano is co-directing the North American Mitochondrial Disease Consortium (NAMDC).

Dr. Hirano serves on the NIH Therapeutic Approaches to Genetic Diseases (TAG) study section, Medical Advisory Committee (MAC) of the Muscular Dystrophy Association, and Scientific Advisory Board of the United Mitochondrial Disease Foundation.

Research Interests

  • Molecular biology of neuromuscular disorders. Positional cloning techniques applied to autosomal disorders affecting the mitochondrial genome. Investigations of mutations of mitochondrial DNA in human cardiomyopathies.

Grants

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DAILY SUBCUTANEOUS INJECTIONS OF ELAMIPRETIDE IN SUBJECTS WITH PRIMARY MITOCHONDRIAL MYOPATHY FOLLOWED BY AN OPEN-LABEL (P&S Industry Clinical Trial)

Mar 1 2018 - Mar 1 2023

A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH PRIMARY MITOCHONDRIAL DISEASE (P&S Industry Clinical Trial)

Jul 21 2017 - Jul 21 2022

OPEN-LABEL EXPANDED ACCESS TRIAL OF DEOXYNUCLEOSIDE THERAPY FOR TK2 DEFICIENCY (Private)

Aug 1 2018 - Jul 31 2021

THERAPEUTIC POTENTIAL OF ENHANCED MITOCHONDRIAL BIOGENESIS FOR PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY (Federal Gov)

Feb 8 2018 - Jan 31 2020

ADULT MDA AND MDA/ALS CARE CENTERS AT COLUMBIA MEDICAL UNIVERSITY MEDICAL CENTER (Private)

Jan 1 2017 - Dec 31 2019

NAMDC: OVERALL RESEARCH PLAN (Federal Gov)

Sep 1 2014 - Aug 31 2019

PEDIATRIC NEUROMUSCULAR CLINICAL RESEARCH NETWORK (Private)

Jul 1 2018 - Jun 30 2019

MITOCHONDRIAL REGULATION OF STRESS REACTIVITY IN HUMANS (Federal Gov)

Jun 1 2017 - May 31 2019

MITOCHONDRIAL ENCEPHALOMYOPATHIES: APPROACHES TO TREATMENT (Federal Gov)

Sep 30 2014 - May 31 2019

MNGIE STUDY (Private)

Jan 31 2018 - Jan 30 2019

DEVELOPMENT OF A COMPLETE PIPELINE FOR MELAS DRUG DISCOVERY (Private)

Dec 17 2015 - Dec 16 2018

THE INHERITED NEUROPATHY CONSORTIUM (INC) RDCRC (Federal Gov)

Jan 1 2018 - Aug 31 2018

SMA FOUNDATION CENTER GRANT (Private)

Jul 1 2015 - Jun 30 2018

AMERICAN MITOCHONDRIAL DISEASE CONSORTIUM PATIENT REGISTRY AND BIOREPOSITORY (Private)

Jul 1 2011 - Jun 30 2018

AMERICAN MITOCHONDRIAL DISEASE CONSORTIUM PATIENT REGISTRY AND BIOREPOSITORY (Private)

Jul 1 2011 - Jun 30 2017

TREATMENT POTENTIAL OF SELECTIVE HDAC6 INHIBITORS IN PAINFUL PERIPHERAL NEUROPATHY (Private)

Jan 1 2016 - Jul 31 2016

NEW YORK COLUMBIA COLLABORATIVE SPOTRIAS (Federal Gov)

Aug 1 2010 - Jul 31 2016

AMERICAN MITOCHONDRIAL DISEASE CONSORTIUM PATIENT REGISTRY AND BIOREPOSITORY (Private)

Jul 1 2011 - Jun 30 2016

THE USE OF EPI-743 IN ACUTELY III PATIENTS WITH INHERITED MITOCHONDRIAL RESPIRATORY CHAIN DISEASE WITHIN 90 DAYS OF (P&S Industry Clinical Trial)

Mar 9 2011 - Mar 9 2016

MITOCHONDRIAL ENCEPHALOMYOPATHIES AND MENTAL RETARDATION (Federal Gov)

Dec 1 1996 - Feb 29 2016

MOLECULAR PATHOGENESIS AND TREATMENT OF MNGIE (Federal Gov)

Apr 1 2010 - Jan 31 2016

SMA FOUNDATION CENTER GRANT (Private)

Jul 1 2015 - Dec 31 2015

DEVELOPMENT OF A COMPLETE PIPELINE FOR MELAS DRUG DISCOVERY (Private)

Jan 1 2014 - Dec 31 2015

METABOLITE BIOMARKER DISCOVERY IN MELAS (Private)

Jan 1 2014 - Dec 31 2015

MOLECULAR BYPASS THERAPY FOR TK2 DEFICIENCY (Private)

Aug 1 2012 - Jul 31 2015

EPI743 TREATMENT OF ONE MITOCHONDRIAL DISEASE PATIENT (P&S Industry Clinical Trial)

Nov 16 2009 - Nov 16 2014

DEVELOPMENT OF A MITOCHONDRIAL DISEASE PATIENT REGISTRY (Private)

Nov 1 2012 - Oct 31 2014

MELTIMI STUDY(EVALUATION OF INDEBENONE TREATMENT IN PATIENTS WITH MITOCHONDRIAL DISORDERS (P&S Industry Clinical Trial)

Jul 1 2009 - Jul 1 2014

IDENTIFYING MITOCHONDRIAL DNA POLYMORPHISMS THAT CONFER GENETIC SUSCEPTIBILITY TO ZYVOX TOXICITY (Private)

Jul 1 2006 - Mar 31 2014

MOLECULAR PATHOGENESIS OF COENZYME Q10 DEFICIENCY (Federal Gov)

Jan 10 2008 - Dec 31 2013

MOLECULAR PATHOGENESIS OF SCAPULOPERONEAL MYOPATHY DUE TO FH L1 MUTATIONS (Private)

Jan 1 2009 - Feb 29 2012

MOLECULAR PATHOGENESIS OF SCAPULOPERONEAL MYOPATHY DUE TO FH L1 MUTATIONS (Private)

Jan 1 2009 - Feb 29 2012

HARLEM HOSPITAL AFFILIATION CONTRACT - GENERAL (NY Local Gov)

Jul 1 2005 - Jun 30 2008